Amanta Healthcare Limited reported a year-on-year increase in total income from operations to ₹6,944.62 lakh for the quarter ended June 30, 2026 (Q1FY27), up from ₹6,626.80 lakh in the corresponding period of the previous year. Profit After Tax (PAT) stood at ₹331.05 lakh, down from ₹350.72 lakh in Q1FY26. The company attributed the margin compression to higher raw material and employee costs, alongside increased finance expenses linked to a new solar term loan. These financial results were approved by the Board of Directors on August 5, 2026, and filed with the stock exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The filing confirms that the unaudited financial results have been reviewed by the Audit Committee and prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34). Amanta Healthcare operates in a single reportable segment: the manufacturing and sale of pharmaceutical products, including contract manufacturing services, as per Ind AS 108 "Operating Segments". Bhavesh Patel, Chairman & Managing Director, stated that while operational performance remained resilient, the bottom line was impacted by inflationary pressures and financing costs associated with the new Solar Term Loan.

Financial Performance Highlights

Total income from operations rose to ₹6,944.62 lakh in Q1FY27 from ₹6,626.80 lakh in Q1FY26. Net profit before tax declined to ₹449.23 lakh from ₹492.65 lakh. Post-tax net profit fell to ₹331.05 lakh from ₹350.72 lakh. Total comprehensive income for the period was ₹312.98 lakh, compared to ₹340.68 lakh in the previous year’s quarter. Earnings per share (basic and diluted) were ₹0.85, down from ₹1.22 in Q1FY26.

The following table summarizes the key financial metrics for the quarter:

Capacity Expansion and Strategic Initiatives

Amanta Healthcare is advancing its capacity expansion plans to drive future growth. The SteriPort plant, utilizing Injection Stretch Blow Moulding (ISBM) technology, is expected to be commissioned by Q2FY27. Additionally, the Small Volume Parenterals (SVP) expansion is targeted for commissioning in Q4FY27. These initiatives are projected to materially enhance manufacturing capacity and operating leverage.

The company also commenced captive solar power generation at its Hariyala, Gujarat facility. While this initiative has led to increased finance costs in the short term due to term loans, management expects it to structurally lower long-term power costs and improve overall cost efficiency. Amanta operates six Large Volume Parenteral (LVP) lines with a capacity of 12.28 crore bottles and three SVP lines with a capacity of 20.91 crore units.

What the Numbers Show

The divergence between top-line growth and bottom-line contraction underscores the impact of input cost inflation and financing decisions on near-term profitability. While revenue grew by 4.79% without additional capacity, the inability to fully offset rising raw material and employee costs resulted in a decline in net profit margins. The strategic shift toward captive solar power represents a long-term bet on cost stability, though it has temporarily weighed on PAT through higher interest outflows. The upcoming commissioning of the SteriPort and SVP expansions in FY27 will be critical in testing whether fixed-cost leverage can reverse the current margin trend as utilization scales up.

Amanta Healthcare Limited has appointed Nilesh Punjabi as Senior Management Personnel (SMP), a decision approved by the Board of Directors during their meeting held on August 5, 2026. The appointment was recommended by the Nomination and Remuneration Committee and disclosed to the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Punjabi, currently serving as Assistant Vice President (HR & Admin), joins the senior management team with extensive industry experience. His inclusion in the SMP cadre is part of the company's governance framework, ensuring that key functional heads are integrated into the highest levels of corporate oversight and communication with regulators.

The regulatory filing, submitted to both BSE Limited and National Stock Exchange of India Limited, cites SEBI Master Circular No. HO/49/14/14(7)2025-CFDPD2/I/3762/2026 dated January 30, 2026, as the governing guideline for this disclosure. The Company Secretary & Compliance Officer, Nikhita Dinodia, signed off on the intimation, confirming the details required under the Listing Regulations.

Profile of Appointee

Nilesh Punjabi brings over 20 years of diverse industry experience to Amanta Healthcare. He holds an MBA in Human Resource Development from South Gujarat University and a Post Graduate degree in HRM from XLRI Jamshedpur.

His career includes significant leadership roles at several premier organizations:

The appointment does not involve any new relationships between directors, as noted in the disclosure annexure. This structural change strengthens the company's human resources governance at the senior management level.